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The subcellular distribution of Tor1p and Tor2p, two
phosphatidylinositol kinase homologs and targets of the
immunosuppressive drug rapamycin in Saccharomyces
cerevisiae, was analyzed. We found that Tor protein is
peripherally associated with membranes. Subcellular
fractionation and immunofluorescence studies showed
that Tor1p and Tor2p associate with the plasma mem-
brane and a second fraction that is distinct from Golgi,
vacuoles, mitochondria, and nucleus and may represent
vesicular structures. Pulse-chase experiments showed
that association of Tor protein with plasma membrane
and the second compartment is fast, does not appear to
involve components of endocytic, secretory, or Golgi to
vacuole transport pathways, and is not affected by the
immunosuppressive drug rapamycin. Deletion analysis
reveals that two domains within Tor2p independently
mediate localization to both compartments. These do-
mains are composed of HEAT repeats that are thought
to act as protein-protein interaction surfaces. Our stud-
ies therefore place Tor proteins at the site of action of
their known downstream effectors and suggest that they
may be part of a multiprotein complex.
The Saccharomyces cerevisiae Tor1p1 and Tor2p proteins are
components of a novel signaling pathway that controls cell
growth in response to nutrient availability (1, 2). Tor1p and
Tor2p were originally identified by dominant mutations that
confer resistance to the immunosuppressive drug rapamycin,
and were later shown to be the physical targets of the FKBP12-
rapamycin complex (3–9). Tor1p and Tor2p are highly homol-
ogous and members of the phosphatidylinositol kinase-related
kinase family (10). Phosphatidylinositol kinase-related kinases
despite their homology to phosphatidylinositol 3- and 4-kinases
are thought to function as protein kinases (11).
Tor2p is an essential protein that regulates cell growth in
two ways. First, it acts redundantly with Tor1p in a nutrient-
sensing signaling cascade that is required for translation ini-
tiation and G1 progression. This function is inhibited by rapa-
mycin (1, 2). Second, Tor2p is also required for cell cycle-
dependent reorganization of the actin cytoskeleton (12, 13).
This function is unique to Tor2p, also essential, and is not
sensitive to rapamycin. Accordingly, yeast cells lacking Tor1p
and Tor2p activity or cells treated with rapamycin exhibit a
dramatic reduction in translation initiation, and show all char-
acteristics of nutrient-starved cells, including arrest in the
early G1 phase of the cell cycle, accumulation of the storage
carbohydrate glycogen, degradation of amino acid transporters,
transcriptional and morphological changes, down-regulation of
ribosome biogenesis, and autophagy (14–20). Loss of Tor2p
function alone, on the other hand, leads to arrest throughout
the cell cycle and depolarization of the actin cytoskeleton
(12, 13, 21).
The Tor signaling pathway appears to be evolutionarily con-
served. The mammalian homolog mTOR, also known as FRAP/
RAFT1/RAPT1, is highly related and acts in a rapamycin-
sensitive signaling pathway that modulates translation
initiation in response to mitogens or amino acid availability (2,
22–25). mTOR regulates translation by activating 70-kDa S6
kinase and inducing phosphorylation of the translational re-
pressor 4E-BP1/PHAS-I which, in turn, leads to dissociation of
4E-BP from eIF-4E and initiation of translation (1, 2, 26). So
far, no direct role of mTOR in the regulation of actin dynamics
has been demonstrated.
The mechanisms by which Tor coordinately regulates diverse
cellular responses to nutrient availability are not precisely
understood. Tor kinase activity controls the association of the
phosphatase-associated factor Tap42p with type 2A and type
2A-related phosphatases (27–29). Tap42-mediated inhibition of
phosphatase activity in turn prevents nuclear accumulation of
nutrient-regulated transcription factors, inhibits degradation
of amino acid transporters, and positively regulates translation
initiation by modulating the phosphorylation status of down-
stream effectors (16–19). Tor2p, in addition, regulates actin
reorganization via activation of Rom2p, a GTP exchange factor
for the small GTPases Rho1p and Rho2p (12, 13). Furthermore,
Mss4p, a phosphatidylinositol 4-phosphate 5-kinase, and
Plc1p, the yeast homolog of phospholipase C, have been impli-
cated in the Tor signaling pathway suggesting a role for phos-
phoinositides and their metabolites in Tor function (21, 30).
However, precisely how Tor1p and Tor2p are activated is not
known, and no immediate downstream effectors that execute
the Tor2p actin cytoskeleton function have been identified.
To gain a better understanding of Tor function, we examined
the subcellular distribution of Tor1p and Tor2p and character-
ized domains within Tor2p that mediate localization. Here we
show that Tor1p and Tor2p are peripheral membrane proteins
that associate with the plasma membrane and a second com-
partment of high buoyant density. Tor localization to both
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compartments is likely via a soluble intermediate and, in the
case of Tor2p, is independently mediated by multiple regions
composed of HEAT repeats. HEAT repeat motifs have previ-
ously been implicated in mediating protein-protein interactions
suggesting that Tor2p may be part of a membrane-associated
protein complex.
EXPERIMENTAL PROCEDURES
Strains, Plasmids, Media, and Reagents—The complete genotypes of
yeast strains and a description of the plasmids used in this study are
listed in Table I. Yeast strains were grown at 30 °C unless otherwise
indicated. The composition of rich (YP media) or synthetic minimal
media (SD) supplemented with the appropriate nutrients was as de-
scribed (31). Rapamycin (kindly provided by Sandoz Pharma, Basel)
was kept as a stock solution (1 mg/ml in ethanol) at 280 °C and was
added to the medium to a final concentration of 0.2 mg/ml. Concanavalin
A (fraction IV), aprotinin, chymostatin, leupeptin, pepstatin, and phen-
ylmethylsulfonyl fluoride were obtained from Sigma. Recombinant lyti-
case was a gift from H. Riezman (Biozentrum, Basel). Zymolyase 20T
was purchased from ICN Immunobiologicals (Irvine, CA). Protein A-
Sepharose was from Amersham Pharmacia Biotech. Easytag
EXPRE35S35S protein labeling mix was purchased from PerkinElmer
Life Sciences. Mouse monoclonal antibody HA.11 or rabbit polyclonal
antibodies directed against the HA tag were purchased from Berkeley
Antibody Co. (Berkeley, CA). FITC-conjugated goat anti-rabbit IgG,
Texas Red-labeled streptavidin, and mouse monoclonal anti-Vph1 and
anti-alkaline phosphatase antisera were purchased from Molecular
Probes (Eugene, OR). Rabbit anti-Cpy1p antiserum was kindly pro-
vided by S. Emr (University of California, San Diego); rabbit anti-
Pma1p antiserum was from S. Gasser (Swiss Institute for Experimental
Cancer Research, Lausanne, Switzerland); rabbit anti-Emp47p was
provided by S. Schro¨der (Biozentrum, Basel, Switzerland); rabbit anti-
Wbp1p antiserum was obtained from M. Aebi (ETH, Zu¨rich, Switzer-
land); rabbit anti-hexokinase and anti-porin antisera were kindly pro-
vided by G. Schatz (Biozentrum, Basel, Switzerland).
Preparation of Polyclonal Antisera Directed against Tor1p and
Tor2p—Polyclonal antisera against the C termini of Tor1p and Tor2p
were raised against Escherichia coli-produced His6-tagged fusion pro-
teins containing amino acids 1680–2470 of Tor1p and amino acids
1683–2474 of Tor2p, respectively. To generate anti-peptide Tor2p anti-
serum, a synthetic peptide containing amino acids 16–29 of Tor2p
(H2N-Cys-Ser-Leu-Arg-Gln-Arg-Ala-Glu-Gly-Lys-His-Arg-Thr-Arg-
Lys-COOH) was coupled to keyhole limpet hemocyanin by N-maleim-
idobenzoyl-N-hydrosuccinimide ester cross-linking. The resulting pep-
tide/keyhole limpet hemocyanin conjugate or recombinant His6-Tor1p
and -Tor2p proteins were injected subcutaneously into female New
Zealand White rabbits (SAVO, Germany). Injection of antigen in incom-
plete Freud’s adjuvant was repeated at least five times, once every 4
weeks. The resulting antisera were tested and titered by Western blot
and immunoprecipitation experiments of yeast cell extracts.
Cell Labeling and Biochemical Extraction of Tor—Unless otherwise
indicated, yeast cells were grown at 30 °C in SD medium substituted
with the appropriate amino acids and lacking methionine (SD-Met) to
TABLE I
Yeast strains and plasmids
Strain Genotype
JK9–3da MATa leu2–3,112 ura3–52 rme1 trp1 his4 GAL
HMLa
MH349–3d JK9–3da tor1<LEU2–4
JK350–18a JK9–3da ade2 tor2<ADE2/pJK5
MB55–4b MATa his4 tor2<ADE2 rot1–1
Plasmid Description
p6HIS-TOR1 5pAS12, 6HIS-TOR1 under control of the GAL1 promoter in pSEYC68 (amprURA3 CEN)
pHA-TOR1 5pYDF125, HA-TOR1 under the control of the GAL1 promoter (39)
p6HIS-TOR2 5pAS10, 6HIS-TOR2 under control of the GAL1 promoter in pSEYC68 (12)
pHA-TOR2 5pAS21, HA-TOR2 under the control of the GAL1 promoter in YCplac33 (amprURA3 CEN)
pTOR2(D2463–2474) 5pJK13, TOR2(D2463–2474) under control of the GAL1 promoter in pSEYC68; made by replacing the
corresponding wild-type fragment in TOR2 with a 3.0-kb SalI restriction fragment of plasmid pJK10
pTOR2(D1946–2474) 5pJK16, TOR2(D1946–2474) under control of the GAL1 promoter in pSEYC68; obtained by deletion of
a 3.0-kb SalI restriction fragment from p6HIS-TOR2
pTOR2(D1390–2474) 5pAS151, TOR2(D1390–2474) under control of the GAL1 promoter in pSEYC68; constructed by
subcloning a 4.5-kb SphI restriction fragment obtained from plasmid pJK5 into the SphI site of
plasmid pAS150
pTOR2(D327–2474) 5pAS150, TOR2(D327–2474) under control of the GAL1 promoter in pSEYC68; a 1.0-kb fragment of
TOR2 was amplified by PCR using Vent polymerase and primers 59-GATTTCTGATCTTTACTTTC
and 59-CCTCTCGAGTGAAAAATGAATAAATACATTAAC. The resulting PCR product was cut with
XhoI and SphI and subcloned into the SalI and SphI sites of pSEYC68
pTOR2(D327–1389) 5pAS152, TOR2(D327–1389) under control of the GAL1 promoter in pSEYC68; obtained by deleting
the internal 4.5-kb SphI restriction fragment from plasmid p6HIS-TOR2
pTOR2(D1–155) 5pJK19, TOR2(D1–155) under control of the GAL1 promoter in pSEYC68; obtained by PCR
amplification of a 5.0-kb fragment of TOR2 using Vent polymerase and primers 59-
CGGGATCCATGACTCTGATCTCATTCTACCTGAGTAC and 59-GAGGAAGCGTTTGAGCTATCATA.
The PCR product was cleaved with BamHI and subcloned into the BamHI site of pSEYC68
pTOR2(D1–326) 5pJK20, TOR2(D1–326) under control of the GAL1 promoter in pSEYC68; generated by PCR
amplification of a 4.1-kb fragment of TOR2 using Vent polymerase and primers 59-CGGGATCCATG-
GATTCAGTGCATGCTACTC and 59-GAGGAAGCGTTTGAGCTATCATA. The PCR product was
cleaved with BamHI and subcloned into the BamHI site of pSEYC68
pTOR2(D1–1690) 5pJK43, TOR2(D1–1690) under control of the GAL1 promoter in pSEYC68; generated by deletion of a
4.8-kb BamHI restriction fragment from plasmid pJK5
pTOR2(487–2239) 5pJK41, TOR2(487–2239) under control of the GAL1 promoter in pSEYC68; generated by subcloning a
5.3-kb BglII restriction fragment into the BamHI site of pSEYC68
pTOR2(326–1945) 5pJK27, TOR2(326–1945) under control of the GAL1 promoter in pSEYC68; generated by deleting a
3.0-kb SalI restriction fragment from plasmid pTOR2(D1–326)
pJK5 TOR2 under control of the GAL1 promoter in pSEYC68 (5)
pJK9 3.0-kb SalI fragment of TOR2 in pSEYC18 (amprURA3 2m) (12)
pJK10 BglII deletion of plasmid pJK9
pJK14 Same as pJK9, but containing TOR2D2463–2474; constructed by replacing the codon encoding C2463 in
TOR2 with an AMBER codon by PCR overlap mutagenesis using mutagenic primers 59-
CCTATCCCAACATTATATCGGTTGGTCTCCATTC and 59-
GAATGGAGACCAACCGATATAATGTTGGGATAGG and flanking primers 59-
CCACAACGCATGATGCCA and 59-GTCTTCACTTACGCCCTA spanning BglII sites in TOR2. The
resulting PCR product was cleaved with BglII and subcloned into the BglII site of plasmid pJK10
Tor Localization37012
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an absorbance at 600 nm (A600) of 0.5. Typically, 10 A600 units of cells
were collected by centrifugation and resuspended in 1 ml of SD-Met
medium. 120 mCi of Easytag EXPRE35S35S protein labeling mix were
added, and cells were incubated for 20 min at 30 °C. A chase period was
initiated by the addition of pre-warmed YPD medium (to A600 of 0.5),
and incubation was continued for 30 min or as otherwise stated. The
chase was terminated by addition of NaN3 and NaF to a final concen-
tration of 10 mM each. Cells were centrifuged and washed once in 10 mM
NaN3, 10 mM NaF. Cell pellets were then resuspended in 15 ml of
spheroplast I buffer (25 mM AMP-PIPES, pH 6.8, 0.6 M sorbitol, 140 mM
cysteamine HCl, 5 mM EDTA, 10 mM NaN3, 10 mM NaF), incubated at
room temperature for 10 min, collected by centrifugation, and converted
to spheroplasts by lyticase digestion in spheroplast II buffer (25 mM
AMP-PIPES, pH 6.8, 1.2 M sorbitol, 140 mM cysteamine HCl, 5 mM
EDTA, 10 mM NaN3, 10 mM NaF) during a 60-min incubation at 30 °C.
Spheroplasts were harvested by centrifugation at 500 3 g at 4 °C,
resuspended in ice-cold lysis buffer (0.8 M sorbitol, 50 mM Tris-Cl, pH
7.5, 50 mM KOAc, 1 mM EDTA, 1 mM dithiothreitol, 1 mg/ml aprotinin,
1 mg/ml leupeptin, 1 mg/ml pepstatin, 1 mM phenylmethylsulfonyl flu-
oride), and homogenized by pulling 10 times through a 23-gauge sy-
ringe. Unbroken cells were removed by centrifugation at 500 3 g at 4 °C
for 10 min. To determine the nature of association of Tor proteins with
the high speed 100,000 3 g (P100) fraction, aliquots corresponding to 10
A600 of the cleared lysate were adjusted to 1 M NaCl, 1% Triton X-100,
1 M NaCl 1 1% Triton X-100, 0.1 M NaCO3, pH 11.0, 5 M urea, 1 M
hydroxylamine, pH 8.0, or left untreated. After incubation on ice for 10
min, the samples were subjected to a 100,000 3 g spin for 45 min at
4 °C.
Immunoprecipitations, SDS-PAGE, and Western Blot Analysis—P13,
P100, and PM fractions were directly resuspended in immunoprecipi-
tation boiling buffer (50 mM Tris, pH 7.5, 1 mM EDTA, 1% SDS),
whereas proteins present in the S100 supernatant fractions or in su-
crose gradient fractions were first precipitated with trichloroacetic acid
at a final concentration of 6%. Proteins were denatured by heating to
65 °C for 10 min and subjected to immunoprecipitation in 10 ml of
TNET (1% Triton X-100, 100 mM Tris-Cl, pH 8.0, 100 mM NaCl, 5 mM
EDTA). Fractions were first precleared by incubation with Sepharose
CL-4B (Sigma), and then antiserum and protein A-Sepharose CL4B
were added, and immunoprecipitations were incubated at 4 °C for 6 h to
overnight with shaking. Tor1p and Tor2p were immunoprecipitated
using the anti-Tor1p C-terminal antiserum and the anti-peptide Tor2p
antiserum, respectively, except for the analysis of N-terminally trun-
cated Tor2p mutants. In this case, the anti-Tor2p C-terminal antiserum
was used. Antisera other than the anti-Tor1p or anti-Tor2p antisera
were used according to personal recommendations to ensure quantita-
tive immunoprecipitation of a given antigen. Immune complexes were
recovered by centrifugation and washed five times with TNET before
SDS-PAGE sample buffer was added. Samples were heated to 65 °C for
5 min to dissociate the immune complex. Immunoprecipitates were
resolved by SDS-PAGE and analyzed and quantitated on a Phospho-
rImager using ImageQuant version 3.2 software (Molecular Dynamics,
Sunnyvale, CA). Western blot analysis was performed using the ECL
system and goat anti-mouse horseradish peroxidase-conjugated IgG as
the secondary antibody (Amersham Pharmacia Biotech). Western blots
were quantitated using densitometric scanning (Molecular Dynamics,
Sunnyvale, CA).
Subcellular Fractionation and Sucrose Density Centrifugation—For
differential fractionation and sucrose density centrifugation, cell-free
extracts corresponding to 100 A600 of
35S-labeled cells were prepared as
described above and subjected to sequential centrifugations at 13,000 3
g for 10 min at 4 °C and at 100,000 3 g for 45 min at 4 °C. Aliquots of
each fraction were removed for further analysis by immunoprecipita-
tion. The remainder of the P13 and P100 pellet fractions was resus-
pended in 0.5 ml of 60% sucrose (w/w in 20 mM HEPES, pH 7.2), placed
on the bottom of a Beckman ultraclear ultracentrifugation tube (Beck-
man Instruments, Fullerton, CA), and overlaid with 0.5-ml steps of 54,
50, 46, 42, 38, 34, 30, 26, 22, and 18% sucrose (w/w in 20 mM HEPES,
pH 7.2). The gradients were centrifuged for 17 h at 170,000 3 g in a
TST55.1 rotor at 3 °C. After centrifugation, 0.33-ml fractions were
collected manually from the top of the gradient. The pellet fraction was
resuspended in the last fraction. The sucrose concentration was deter-
mined by measuring the refractive index.
For the analysis of Tor2p deletion variants, yeast cells carrying the
mutant variants were grown overnight in selective raffinose medium,
diluted into galactose medium (3% final concentration), and incubated
an additional 4 h at 30 °C. 20 A600 units of cells were
35S-labeled,
chased, converted to spheroplasts, and lysed as described above. Cell-
free extracts were prepared and separated into P13, P100, and S100
fractions as described above, and the distribution of Tor2 deletion
variants was determined by immunoprecipitation and analysis on the
PhosphorImager.
Preparation of Plasma Membrane Fractions and Pulse-Chase Exper-
iments—Aliquots of 40 A600 units of yeast cells were labeled with
Easytag EXPRE35S35S protein labeling mix for 1 min at 30 °C, collected
by centrifugation for 2 s in a microcentrifuge, resuspended in 50 ml of
pre-warmed YPD medium, and incubated at 30 °C. Cells were har-
vested after 15, 30, and 60 min after initiating the chase, resuspended
in 10 mM NaN3, 10 mM NaF supplemented with cycloheximide (10
mg/ml) to inhibit new protein synthesis, and kept on ice. Cells from the
0-min time point were directly resuspended in 10 mM NaN3, 10 mM NaF
containing cycloheximide (10 mg/ml) and kept on ice. Cells from each
time point were then converted to spheroplasts, coated with ConA in the
presence of cycloheximide, washed, and resuspended in ice-cold lysis
buffer essentially as described (32). Extracts were homogenized by
pulling 10 times through a 23-gauge needle. The low speed plasma
membrane (PM) fraction, and the high speed P100 and S100 fractions
were obtained by sequential centrifugation as described (32). The ex-
tent of cell lysis was determined by analyzing the percent of the cyto-
solic protein hexokinase that was recovered in the PM and P100 frac-
tions. The amount of radioactivity in the PM, P100, and S100 fractions
was expressed as percent of total radioactivity in the lysate after cor-
rection for cell lysis.
Indirect Immunofluorescence Microscopy—For visualization of HA-
Tor1p and HA-Tor2p, yeast cells transformed with plasmid pYDF125 or
pAS21 were grown overnight under selective conditions in SRaffinose
medium, diluted into YPGal medium to induce expression of the HA
fusion proteins, and cells were grown for 4–5 h to early logarithmic
phase at 30 °C. This resulted in a 4–5-fold overexpression of the tagged
protein compared with endogenous protein as estimated by Western
blot analysis of cell extracts. Indirect immunofluorescence on whole
fixed yeast cells was performed using standard procedures (18). HA-
Tor1p and HA-Tor2p were visualized by anti-HA mouse monoclonal
antibody HA.11 followed by FITC-conjugated goat anti-mouse IgG. For
double labeling, HA-Tor1p and HA-Tor2p were visualized by anti-HA
rabbit polyclonal antibodies followed by FITC-conjugated goat anti-
rabbit IgG. Alkaline phosphatase was visualized by incubation with a
monoclonal mouse anti-alkaline phosphatase antibody followed by bi-
otinylated secondary antibody in combination with Texas Red-labeled
streptavidin. DNA was stained with DAPI. The samples were viewed
through a 603 lens using a Zeiss axioplan microscope (Carl Zeiss, Inc.,
Thornwood, NY). Confocal sections were collected using a laser-scan-
ning confocal microscope consisting of a Bio-Rad MR 1000 scanhead
mounted transversely to an inverted Nikon Diaphot 200. The micro-
scope was controlled by the Bio-Rad’s Lasersharp 3.0 program, which
provided data acquisition and processing.
RESULTS
Detection of Tor1p and Tor2p—To aid in the molecular anal-
ysis of Tor function, we generated antibodies that specifically
recognize Tor1p or Tor2p. Tor1p-specific antibodies were raised
against the C-terminal kinase domain of Tor1p, whereas the
antiserum against Tor2p was raised against a synthetic pep-
tide corresponding to a unique N-terminal sequence of Tor2p.
The anti-Tor1p antiserum immunoprecipitated a single
polypeptide with an apparent molecular mass of 250 kDa (pre-
dicted size, 284 kDa) from 35S-labeled wild-type extracts (Fig.
1A, lane 1). The same protein was also isolated from extracts
derived from cells harboring a tor2 disruption (Fig. 1A, lane 3)
but not from extracts generated from cells that carried a tor1
deletion mutation (Fig. 1A, lane 2). When TOR1 was overex-
pressed under the control of the GAL1 promoter, up to 5-fold
higher levels of the 250-kDa species were recovered (data not
shown), whereas no protein was immunoprecipitated with pre-
immune serum (data not shown).
The anti-Tor2p antiserum specifically immunoprecipitated a
single protein that migrated at approximately 250 kDa (pre-
dicted mass, 285 kDa) from 35S-labeled wild-type cells (Fig. 1B,
lane 1). This protein was also immunoprecipitated from an
extract derived from a tor1 disruption strain (Fig. 1B, lane 2)
but not from an extract generated from a tor2 mutant strain
(Fig. 1B, lane 3). A 170-kDa polypeptide was immunoprecipi-
tated from this strain instead, which corresponds in its mass to
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the predicted truncated Tor2p protein encompassing the N
terminus up to the insertion point of the ADE2 disruption
marker (Fig. 1B, lane 3). Overexpression of TOR2 on a multi-
copy plasmid led to the recovery of up to 10-fold stronger signal
(data not shown). The 250-kDa species was, however, not re-
covered when preimmune serum was used or when excess
peptide against which the anti-Tor2p antibodies were raised
was present during immunoprecipitation (data not shown).
Taken together, these results demonstrate that the anti-Tor1p
and anti-Tor2p antisera specifically recognize endogenous
Tor1p and Tor2p, respectively.
Tor1p and Tor2p Fractionate as Peripheral Membrane Pro-
teins—As a first step to localize Tor1p and Tor2p, a 35S-labeled
extract derived from wild-type cells was fractionated into
100,000 3 g cytosolic supernatant (S100) and membrane-en-
riched particulate (P100) fractions. These fractions were
probed by immunoprecipitation for the presence of Tor1p and
Tor2p. We found that Tor1p and Tor2p mainly partition into
the particulate fraction (Fig. 2 and Table II) with only minor
amounts (5–10% of either Tor1p or Tor2p) detected in the
soluble fraction. Overexpression of Tor1p or Tor2p led to the
recovery of higher levels of Tor proteins in the soluble fraction
(20–30% in the Tor overproducing cells (Table II) compared
with 5–10% in wild-type cells) which could indicate that asso-
ciation of Tor with the particulate fraction is saturable.
To determine the nature of the association of Tor protein
with the particulate fraction, a 35S-labeled extract was divided
into aliquots and treated with a set of reagents prior to centrif-
ugation at 100,000 3 g. The distribution of Tor1p, Tor2p, and
the integral plasma membrane H1-ATPase Pma1p between
the P100 and S100 fractions was then monitored by immuno-
precipitation. As expected, Pma1p was extracted into the S100
fraction only by treatment with the nonionic detergent Triton
X-100, but not by reagents that disrupt protein-protein inter-
actions (Table II). In contrast, Tor1p and Tor2p were only
partially extracted with Triton X-100 (1%) (Fig. 2 and Table II),
whereas high salt (1 M NaCl), alkaline pH (0.1 M NaCO3, pH
11), or the chaotropic agent urea which disrupts protein-pro-
tein interactions released the majority of Tor1p and Tor2p into
the soluble fraction (Fig. 2 and Table II). 1 M hydroxylamine,
which cleaves thioester bonds between fatty acids and proteins
(33), did not solubilize Tor1p or Tor2p (data not shown). These
data together suggest that Tor1p and Tor2p are peripheral
membrane proteins. This is consistent with the absence of
predicted signal sequences or transmembrane domains in
Tor1p and Tor2p.
Tor1p and Tor2p Localize to the Plasma Membrane and a
Second Subcellular Compartment—Subcellular fractionation
studies were carried out to identify more precisely the intra-
cellular location of Tor1p and Tor2p. Wild-type cells were
pulse-labeled with [35S]Met/Cys, converted to spheroplasts, os-
motically lysed, and unbroken cells were removed by low speed
centrifugation. The cell-free extract was then sequentially cen-
trifuged at 13,000 and 100,000 3 g to generate the membrane-
enriched particulate P13 and P100 fractions, as well as the
cytosolic S100 supernatant fraction. The presence of Tor1p and
Tor2p, as well as of a set of organelle marker proteins was
determined in each fraction by immunoprecipitation.
The P13 fraction is highly enriched for plasma membrane,
endoplasmic reticulum (ER), vacuoles, and mitochondria,
whereas the P100 fraction is highly enriched for Golgi, endo-
somes, and secretory vesicles (Table III (34)). We found that
almost all of the plasma membrane marker Pma1p, the ER
membrane marker Wbp1p, the vacuolar membrane marker
Vph1, and the mitochondrial outer membrane marker porin
were present in the P13 fraction (Table III). The Golgi mem-
brane marker Emp47p, in contrast, was almost exclusively
found in the P100 fraction (Table III). The portion of Emp47p in
the P13 fraction represents the ER-localized precursor form
that is typically detected under the growth conditions used for
these experiments (35). Tor1p or Tor2p were found to distribute
equally between the P13 and P100 pellet fractions with only
trace amounts present in the soluble fraction (Table III). The
fractionation behavior of Tor1p and Tor2p is therefore different
from that observed for specific organelle markers and could
indicate that Tor proteins are present in more than one
compartment.
To identify the subcellular membranous compartment(s)
with which Tor1p and Tor2p associate, P13 and P100 fractions
were resuspended in 60% sucrose and subfractionated by equi-
librium flotation in continuous 18–54% sucrose density gradi-
ents. The gradients were fractionated and analyzed for the
distribution of Tor1p, Tor2p, and various organelle markers.
Tor1p and Tor2p present in the P13 fraction cofractionated
with each other and the plasma membrane marker Pma1p
(Fig. 3). Both Tor proteins clearly fractionated in a manner
distinct from vacuolar (Cpy1p) and mitochondrial (porin) mark-
ers and were also partially resolved from the ER membrane
marker Wbp1p (Fig. 3A and data not shown). In the P100
fraction, Tor1p and Tor2p were present in fractions that were
clearly distinct from fractions containing the Golgi marker
Emp47p (Fig. 3B). Furthermore, both Tor proteins were again
at least partially resolved from the ER marker Wbp1p (Fig.
3B). Similar results were obtained when yeast extracts were
resolved by velocity gradient centrifugation (data not shown).
In summary, Tor1p and Tor2p appear to colocalize to two
biochemically distinct subcellular compartments one of which
FIG. 1. Identification of Tor1p and Tor2p. Lysates prepared from
10 A600 of
35S-labeled wild-type (wt; strain JK9-3da) cells or cells con-
taining either a tor1 (Dtor1, strain MH349-3b) or a tor2 (Dtor2; strain
MB55-4b) deletion mutation were subjected to denaturing immunopre-
cipitation using polyclonal anti-Tor1p or anti-Tor2p antibodies. Immu-
noprecipitates were resolved by SDS-PAGE and analyzed on the Phos-
phorImager. The position and molecular weights (3103) of prestained
standards are indicated at the left. MB55-4b also contains a mutation in
the ROT1 gene that allows tor2-deficient cells to live (53).
FIG. 2. Tor1p and Tor2p fractionate as peripheral membrane
proteins. A cell extract prepared from 60 A600 of
35S-labeled wild-type
yeast cells was divided into aliquots and treated with the indicated
reagent for 10 min on ice as described under “Experimental Proce-
dures.” Extracts were then separated into 100,000 3 g supernatant and
pellet fractions, and Tor1p and Tor2p were immunoprecipitated from
these fractions, resolved by SDS-PAGE, and analyzed on the Phospho-
rImager. S and P denote the 100,000 3 g supernatant and pellet
fractions, respectively. The position and molecular weights (3103) of
prestained standards are indicated at the left. TX-100, Triton X-100.
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contains the plasma membrane.
We then purified plasma membrane by an independent
method (32). This method is based on the coating of 35S-labeled
yeast spheroplasts with the lectin ConA that binds glycopro-
teins and selectively labels plasma membranes of intact cells.
After cell lysis, the dense ConA-coated plasma membrane
sheets can be separated from other cellular membranes by low
speed centrifugation yielding the plasma membrane (PM) frac-
tion. The low speed supernatant fraction is further separated
into the particulate P100 and the cytosolic S100 fractions. By
using this procedure, we were able to obtain a highly purified
plasma membrane fraction (Fig. 4A) that contained only minor
contamination by other organelle markers that was likely due
to the presence of a small amount of unbroken cells in this
fraction as evidenced by the cytosolic marker hexokinase. The
majority of Tor1p and Tor2p copurified with plasma mem-
brane. 50–65% of Tor1p and Tor2p was recovered in the PM
fraction, whereas approximately 35–40% of Tor1p and Tor2p
partitioned into the P100 fraction (Fig. 4A). Only trace
amounts (5–10%) of Tor1p and Tor2p were detected in the
cytosolic S100 fraction. We therefore conclude that more than
half of Tor1p and Tor2p associates with the plasma membrane.
The remaining portion of Tor is found in a different, high
buoyant density fraction.
Tor1p and Tor2 Localization Is Rapid and Does Not Require
Vesicle Transport—The presence of Tor1p and Tor2p in two
distinct fractions may be explained by Tor passaging from one
compartment to another. Alternatively, Tor1p and Tor2p could
simultaneously associate with two compartments upon synthe-
sis. To differentiate between these two possibilities, pulse-
chase experiments were carried out with a labeling period of 1
min and increasing periods of chase with unlabeled amino
acids. After the chase, cells were converted to spheroplasts and
coated with ConA in the presence of cycloheximide to prevent
new protein synthesis. Extracts were then generated and frac-
tionated into PM, P100, and S100 fractions. We found that
newly synthesized Tor1p and Tor2p rapidly partitioned into
the PM and the P100 fractions (Fig. 4B). The majority of Tor1p
and Tor2p was found in the PM and the P100 fractions even
after only a 1-min pulse. The integral plasma membrane H1-
ATPase Pma1p, in contrast, which is transported to the cell
surface via the secretory pathway, starts to accumulate sig-
nificantly in the PM fraction only after 15–30 min of chase
(Fig. 4B).
We also analyzed the subcellular distribution of Tor1p and
Tor2p in a set of mutants defective in various stages of the
secretory (sec4), endocytic (end4), or Golgi to vacuole (vps21,
vps27, vps34, and vps45) protein transport pathways (36–38).
Cells were shifted to the nonpermissive temperature for 1 h to
induce the mutant phenotype, pulse-labeled, lysed, and frac-
tionated by differential centrifugation and velocity gradient
centrifugation as described above. The intracellular distribu-
tion of Tor1p and Tor2p was analyzed and compared with that
in wild-type cells. We found no changes in the fractionation
profiles of Tor1p or Tor2p in these mutants (data not shown).
Thus, together with our findings that functional vesicular
transport pathways are not required for normal Tor localiza-
tion, we conclude that Tor1p and Tor2p associate with both
subcellular sites most likely via a soluble intermediate.
Rapamycin Does Not Affect the Subcellular Localization of
Tor1p and Tor2p—We next investigated whether treatment of
yeast cells with rapamycin alters the intracellular distribution
of Tor1p or Tor2p. Wild-type cells were labeled with [35S]Met/
Cys for 20 min and chased with excess unlabeled amino acids in
the presence of rapamycin (200 ng/ml) or carrier (ethanol) for 1
or 2 h at 30 °C. Microscopic examination of rapamycin-treated
cells confirmed the effectiveness of rapamycin. After 1 h of
rapamycin treatment, cells exhibited a marked increase in size
and contained a single enlarged vacuole. After 2 h of treatment,
cells were primarily arrested as large unbudded cells with
large vacuoles (data not shown) as reported previously (4).
Rapamycin-treated cells were converted to spheroplasts and
coated with ConA to label the plasma membrane. ConA-coated
plasma membrane (PM), particulate P100, and cytosolic S100
fractions were isolated and probed for the presence of Tor1p
and Tor2p. Alternatively, extracts derived from rapamycin-
treated cells were subjected to differential centrifugation and
velocity gradient fractionation, and the fractionation profile of
Tor1p and Tor2p was compared with that of cells treated with
carrier alone. We found, by both methods, that rapamycin
treatment did not affect Tor localization (Fig. 4B and data not
TABLE III
Differential centrifugation
Wild-type cells were 35S-labeled for 20 min, chased for 30 min at
30 °C, lysed, and subjected to differential centrifugation as described
under “Experimental Procedures.” The amount of Tor1p, Tor2p, and
organelle markers in each fraction was determined by quantitative
immunoprecipitation and PhosphorImager analysis. The amount of
Vph1p was determined by Western blot analysis and densitometric
scanning. Numbers indicate percent of total.
Marker protein P13 P100 S100
% % %
Tor1p 55 42 3
Tor2p 53 43 4
Pma1p (plasma membrane) 86 2 12
Wbp1p (endoplasmic reticulum) 78 20 2
Emp47p (Golgi) 8 90 2
Vph1p (vacuolar membrane) 95 3 2
Cpy1p (vacuolar lumen) 48 6 46
Porin (mitochondria) 97 2 1
Hexokinase (cytoplasm) 2 0 98
TABLE II
Association of Tor1p, Tor2p, and Pma1p with the particulate fraction
Wild-type cells were 35S-labeled for 20 min, chased for 30 min at 30 °C and lysed, and the cell lysate was divided into equal aliquots and treated
with the indicated reagents as described under “Experimental Procedures.” After treatment, extracts were separated into S100 and P100 fractions,
and the amounts of Tor proteins and Pma1p in each fraction were determined by quantitative immunoprecipitation and PhosphorImager analysis.
Numbers indicate percent of total.
Tor1p Tor2p Pma1p
S P S P S P
% % %
No treatment, endogenous 6 94 10 90 0 100
No treatment, GAL1 promoter 26 74 28 72
High salt (1 M NaCl) 91 9 88 12 0 100
pH 11 (0.2 M NaCO3) 86 14 92 8 1 99
Urea (5 M) 97 3 93 7 1 99
Triton X-100 (1%) 46 54 49 51 70 30
Triton X-100 1 high salt 98 2 95 5 81 19
S, supernatant; P, pellet.
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shown). Interestingly, rapamycin did appear to delay the trans-
port of Pma1p to the cell surface indicating that the drug might
affect the rate of secretion (Fig. 4B).
Localization of Epitope-tagged Tor1p and Tor2p by Immuno-
fluorescence—We also used immunofluorescence as an inde-
pendent method to localize Tors. Because our initial attempts
to detect endogenous Tor proteins or GFP-Tor expressed under
control of the endogenous promoter failed, Tor1p and Tor2p
were tagged with the HA epitope at their N termini. The
HA-Tor2p fusion protein complements the lethality of a tor2
knock-out mutant2 demonstrating that the tag does not inter-
fere with Tor2p function. HA-Tor1p was previously shown to be
functional in vivo (39). Furthermore, HA-Tor2p cofractionated
with endogenous Tor2p during differential centrifugation and
in sucrose density gradients, demonstrating that overexpres-
sion does not significantly alter subcellular localization (data
not shown). Thus, HA-Tor should accurately reflect the local-
ization of the endogenous protein.
Visualization of HA-Tor1p and HA-Tor2p using monoclonal
anti-HA antibodies revealed a discrete punctate staining at the
cell periphery, as well as a less pronounced internal dot-like
staining (Fig. 5A, and data not shown). No signal was detected
in yeast cells overexpressing untagged Tor protein (data not
shown). Comparison of the anti-HA and DAPI stainings
showed that HA-Tor1p and HA-Tor2p do not localize to the
nucleus or the perinuclear area (Fig. 5B, and data not shown).
Furthermore, neither HA-Tor1p nor HA-Tor2p appears to co-
localize with the vacuolar marker alkaline phosphatase (Fig. 5,
D and E). Confocal microscopy demonstrated that the majority
of HA-Tor1p and HA-Tor2p is localized to the plasma mem-
brane, whereas the remaining portion is distributed through-
out the cell interior in a dot-like pattern (Fig. 5, F and G). Thus,
our immunofluorescence studies are in agreement with our
biochemical fractionation studies and suggest that Tors are
associated with the plasma membrane and another, as yet
2 J. Kunz, U. Schneider, I. Howald, A. Schmidt, and M. N. Hall,
unpublished results.
FIG. 3. Tor1p and Tor2p cofraction-
ate with the plasma membrane
marker Pma1p on sucrose density
gradients. Wild-type cells were 35S-la-
beled and fractionated into P13, P100,
and S100 fractions as described under
“Experimental Procedures.” The P13 (A)
and P100 (B) fractions were individually
resuspended in 60% sucrose and resolved
on a self-forming 18–54% sucrose density
gradient. The sucrose gradients were
fractionated manually from the top (frac-
tion 1) to the bottom (fraction 15 or 16) in
0.33-ml fractions. The pellets were resus-
pended in the last fraction. Density was
measured by refractometry. The distribu-
tion of Tor1p, Tor2p, and organelle
marker proteins in each fraction was de-
termined by quantitative immunoprecipi-
tation and analysis on the PhosphorIm-
ager. Distribution of marker proteins is
expressed as percent of the total pellet-
able counts (P13 1 P100).
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unidentified, location.
Two Regions Containing HEAT Repeats Independently Me-
diate Tor2p Localization—To define the region(s) within Tor2p
that mediates localization, we constructed deletion variants of
Tor2p, and we tested their ability to associate with the partic-
ulate P13 and P100 fractions (summarized in Fig. 6). We found
that an N-terminal fragment containing amino acids 1–326
(Tor2pD327–2474) was sufficient for Tor2p localization. This
fragment appeared to be unstable in yeast, yet associated with
the P13 and P100 fractions in a manner similar to the wild-type
protein. In accordance with this, an internal deletion mutant,
which contained the N-terminal 326 amino acids but lacked a
central domain (Tor2pD327–1389), was stable and behaved
identically in fractionation experiments. The C-terminal ki-
nase homology domain, as well as the FKBP12-rapamycin
binding domain, however, were not required for association of
Tor2p with the P13 and P100 fractions (Tor2pD1690–2474 and
Tor2pD1390–2474).
The N-terminal domain is sufficient but not necessary to
mediate localization. Deletion of amino acids 1–326 did not
result in mislocalization of Tor2p (Tor2pD1–326). This indi-
cates that a second domain within Tor2p independently medi-
ates membrane association and localization. This second region
is located between amino acids 327 and 1690, since a deletion
mutant (Tor2pD1–1690) lacking this region failed to fraction-
ate with the P100 fraction and partitioned entirely into the P13
fraction. This could have indicated that this truncation mutant
still associates with the plasma membrane but lacks the infor-
mation for localization to the second compartment. However,
when analyzed by equilibrium density gradient centrifugation,
Tor2pD1–1690 failed to cofractionate with wild-type Tor2p but
rather segregated into a denser part of the gradient (data not
shown). This suggests that the information for proper subcel-
lular localization is lost in this mutant and that the protein
aberrantly associates with another subcellular compartment.
Further analysis of Tor2p deletion variants (Tor2pD1390–
2474, Tor2p487–2239, and Tor2p326–1945) restricted the sec-
ond domain contributing to Tor2p localization to a region be-
tween amino acids 487 and 1690. In summary, these data
indicate that localization of Tor2p involves two regions that do
not include the kinase domain or the FKBP12-rapamycin-bind-
ing site but contain extensive repeats, termed HEAT repeats
(see below). These HEAT repeat domains can independently
mediate association of Tor2p with both intracellular sites.
DISCUSSION
We investigated the subcellular distribution of Tor1p and
Tor2p by biochemical and immunofluorescence approaches,
and we found that Tor1p and Tor2p similarly distribute to two
biochemically distinct fractions. We have identified one of these
fractions as the plasma membrane. The majority of Tor1p and
Tor2p cofractionated with the integral plasma membrane
FIG. 4. Tor1p and Tor2p associate
with plasma membrane via soluble
intermediate. A, 20 A600 of wild-type
cells were labeled with 35S for 20 min,
chased for 30 min, and PM, membrane-
enriched P100, and cytosolic S100 frac-
tions were prepared as described under
“Experimental Procedures.” Fractions
were probed for Tor1p, Tor2p, and or-
ganelle markers by immunoprecipitation.
Immunoprecipitates were resolved by
SDS-PAGE and analyzed on the Phosphor-
Imager. B, time course of Tor1p, Tor2p, or
Pma1p association with the PM, the
membrane-enriched P100, and the cytoso-
lic S100 fractions. PM, P100, and S100
fractions from 40 A600 of pulse-labeled
ConA-coated spheroplasts were prepared
as described under “Experimental Proce-
dures” and probed for Tor1p, Tor2p, and
Pma1p by immunoprecipitation. Immuno-
precipitates were resolved by SDS-PAGE
and analyzed on the PhosphorImager.
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marker Pma1p during differential centrifugation studies and
on sucrose density equilibrium gradients. Association with
plasma membrane was further substantiated by an independ-
ent procedure using the lectin ConA that selectively binds to
glycoproteins on intact yeast spheroplasts and allows the pu-
rification of highly enriched plasma membrane sheets. 50–65%
of Tor1p and Tor2p was found to purify with plasma mem-
brane, whereas other organelle markers could be clearly sepa-
rated from this fraction. In agreement with the biochemical
data, immunofluorescence staining of HA-Tor1p and HA-Tor2p
was detected at discrete sites at the cell periphery and in a
punctate pattern throughout the cytoplasm.
The localization of Tor1p and Tor2p to the plasma membrane
is consistent with their function. One function of Tor2p is to
control organization of the actin cytoskeleton by activation of a
GTPase switch composed of Rho1p, Rho2p, and the GDP/GTP
exchange factor Rom2p (12, 13). A second function of Tor2p
that is shared with Tor1p is to regulate translation initiation
and G1 progression in response to nutrient availability in yeast.
Both Rom2p and Rho1p have been localized to the plasma
membrane, and Rho1p in addition has also been detected on
Golgi structures and post-Golgi vesicles (40–42). Furthermore,
Mss4p, an essential phosphatidylinositol 4-phosphate 5-kinase
and candidate component of the Tor signaling pathway, is also
localized to the plasma membrane (21, 43, 44). In addition,
Plc1p, the yeast homolog of phospholipase C, has been linked to
both Tor2p functions and may mediate generation of lipid sec-
ond messengers at the plasma membrane (21, 30). The local-
ization of Tor proteins to the plasma membrane is therefore
consistent with the localization of known or suspected down-
stream effectors.
How localization of Tor1p and Tor2p to a second subcellular
site may relate to their function as well as the nature of this
site remains to be determined. Our subcellular fractionation
and indirect immunofluorescence studies demonstrate that
this second site is distinct from mitochondria, nuclei, Golgi, and
vacuoles. Further studies will be required to determine
whether Tor proteins associate with membranes of high buoy-
ant density or with a large protein complex, both of which could
be expected to partition into the P100 fraction.
Cardenas et al. (45) have reported previously that Tor2p is
localized to the surface of yeast vacuoles and that this associ-
ation is disrupted by the immunosuppressive drug rapamycin.
This is in contrast to our results, which show that Tor proteins
are localized to the plasma membrane and a second compart-
ment, which is biochemically distinct from the vacuole. Fur-
thermore, we do not observe an effect of rapamycin on Tor
localization. The reason for the discrepancy between their re-
sults and ours is not known at present. However, we base our
interpretation on several observations. (a) We have demon-
strated that our antisera specifically recognize endogenous
Tor1p or Tor2p and do not cross-react. (b) Our biochemical
fractionation data are consistent with findings obtained by
direct purification of plasma membrane and results obtained
by immunofluorescence studies using epitope-tagged Tor1p
and Tor2p. (c) We do not observe any immediate effects of
rapamycin on Tor2p localization as judged by several independ-
ent methods including differential centrifugation,2 sucrose
density gradient centrifugation,2 purification of plasma mem-
brane, and indirect immunofluorescence.
How do Tor proteins become membrane-bound and reach
their subcellular location? Our extraction data suggest that at
least part of Tor1p and Tor2p are peripheral membrane pro-
teins. Only reagents that disrupt protein-protein interactions
efficiently extract the Tor proteins into a soluble fraction. The
reproducible effect of detergent extraction suggests that the
association of Tor1p and Tor2p with membranes may be com-
plex and may involve both ionic and hydrophobic protein-pro-
tein interactions with a membrane-bound protein(s) or even
protein-lipid interactions. Pulse-chase experiments indicate
that Tor1p and Tor2p associate rapidly and simultaneously
with their final destinations and that this association is most
likely via a soluble intermediate. This is in accordance with our
finding that Tor localization is not altered in yeast mutants
that are defective for endocytic, secretory, or Golgi to vacuole
vesicle trafficking pathways. Thus, association of Tor proteins
with membranes is likely mediated by interaction with an
integral membrane protein or with a membrane-associated
protein complex.
We used deletion analysis of TOR2 to identify the region(s)
that mediate localization and, potentially, may engage in pro-
tein-protein interaction. This analysis identified two domains,
in the N terminus and center of Tor2p, that independently
mediate localization. The most prominent feature in these do-
mains is an extensive stretch of sequence composed of a re-
peated antiparallel a-helical motif, termed HEAT repeat motif
(46). These repeats extend in two blocks (amino acids 100–470
and 560–1220) and encompass the two regions identified by
our deletion analysis as sufficient for mediating localization.
Because Tor1p colocalizes with Tor2p and also contains HEAT
repeats (1, 46), it is likely that similar findings apply to its
localization.
HEAT repeat motifs are highly divergent and have been
detected in a number of proteins, including huntingtin, elon-
gation factor 3, the 65-kDa structural A subunit of protein
phosphatase 2A (PP2A R65/A), the nuclear pore transport pro-
tein importin b, and the splicing factor SAP155, for example,
many of which have a demonstrated or suspected role in vesic-
ular or protein traffic and form multiprotein complexes (46, 47).
The three-dimensional structure of the HEAT repeats in sev-
eral of these proteins has been recently solved and reveals an
extended curved conformation composed of a double layer of
FIG. 5. Intracellular localization of Tor1p and Tor2p. Wild-type
yeast cells transformed with vectors containing HA-TOR1 or HA-TOR2
under the control of the inducible GAL1 promoter were grown at 30 °C
in medium containing glycerol as the carbon source and then shifted to
medium containing galactose to induce expression of the fusion protein.
Cells were incubated for 4–5 h at 30 °C before being fixed and processed
for immunofluorescence. A, indirect immunofluorescence showing HA-
Tor2p; B, HA-Tor2p (green) overlaid with DAPI staining (purple) to
visualize nuclei; C, Nomarski optics to visualize cells; D, HA-Tor1p
(green) overlaid with alkaline phosphatase staining (red) to visualize
vacuoles; E, HA-Tor2p (green) overlaid with alkaline phosphatase stain-
ing (red); F, confocal slice of cells expressing HA-Tor1p; G, confocal slice
of cells expressing HA-Tor2p.
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a-helices (48–51). This structure provides a large exposed sur-
face with a hydrophobic nature that can participate in multiple
protein-protein interactions. Structural data in combination
with biochemical and deletion analysis indicate that groups of
HEAT repeats indeed mediate interactions with distinct bind-
ing partners (48–51).
HEAT repeats domains may, therefore, anchor Tor to the
membrane by mediating interactions with membrane-associ-
ated protein(s). The large and extended surface formed by these
repeats may also provide additional protein-protein interaction
interfaces with effectors or regulatory components. In accord-
ance with such a hypothesis, we found that overexpression of
the central region containing HEAT repeats is detrimental to
yeast cells by interfering with Tor2p function.2
Striking parallels also exist between Tor2p and other pro-
teins containing HEAT repeats. Huntingtin, the protein af-
fected in Huntington’s disease, is a large protein that is local-
ized to multiple subcellular compartments, including vesicular
structures, and interacts with a plethora of proteins involved in
actin cytoskeleton function and possibly vesicular transport
(47). Furthermore, ATM, a Tor-related protein, is localized to
the nucleus and cytoplasmic vesicles and was recently shown to
bind b-adaptin, a protein involved in clathrin-mediated endo-
cytosis (52).
It is therefore tempting to speculate that HEAT repeats in
Tor proteins act as molecular scaffolds for the recruitment of
signaling complexes. The large interaction surface in these
proteins and their localization to multiple cellular compart-
ments may provide a means to integrate several inputs and to
relay signals regulating temporal as well as spatial growth. An
important issue now becomes identification of Tor-interacting
protein(s). Definition of minimal domains that mediate local-
ization should facilitate the isolation of protein(s) that anchor
Tor to membranes and may potentially lead to the identifica-
tion of regulators and additional effectors of the Tor pathway.
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